Veeva Systems Inc (NYSE:VEEV) insider Eleni Nitsa Zuppas sold 1,253 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $103.52, for a total value of $129,710.56. Following the sale, the insider now directly owns 10,151 shares in the company, valued at $1,050,831.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NYSE VEEV traded down $0.35 on Thursday, reaching $100.65. The stock had a trading volume of 26,747 shares, compared to its average volume of 1,179,392. Veeva Systems Inc has a 1 year low of $52.17 and a 1 year high of $105.04. The company has a market capitalization of $14.97 billion, a P/E ratio of 110.54, a price-to-earnings-growth ratio of 4.93 and a beta of 1.54.
Veeva Systems (NYSE:VEEV) last issued its earnings results on Thursday, August 23rd. The technology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.05. Veeva Systems had a return on equity of 14.20% and a net margin of 21.23%. The firm had revenue of $209.60 million for the quarter, compared to the consensus estimate of $203.50 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. The business’s quarterly revenue was up 24.9% compared to the same quarter last year. equities research analysts forecast that Veeva Systems Inc will post 1.1 EPS for the current fiscal year.
A number of brokerages have recently issued reports on VEEV. Zacks Investment Research raised Veeva Systems from a “hold” rating to a “strong-buy” rating and set a $117.00 target price on the stock in a research report on Wednesday, August 29th. ValuEngine raised Veeva Systems from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 28th. Deutsche Bank upped their price target on Veeva Systems from $70.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, August 24th. Needham & Company LLC reissued a “buy” rating and set a $100.00 price target (up from $90.00) on shares of Veeva Systems in a research report on Friday, August 24th. Finally, KeyCorp upped their price target on Veeva Systems from $84.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, August 24th. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $94.29.
Hedge funds and other institutional investors have recently modified their holdings of the business. We Are One Seven LLC grew its stake in Veeva Systems by 147.6% in the first quarter. We Are One Seven LLC now owns 1,679 shares of the technology company’s stock valued at $123,000 after purchasing an additional 1,001 shares in the last quarter. Next Century Growth Investors LLC bought a new stake in shares of Veeva Systems during the 1st quarter worth about $130,000. Flagship Harbor Advisors LLC bought a new stake in shares of Veeva Systems during the 2nd quarter worth about $149,000. Mutual of America Capital Management LLC bought a new stake in shares of Veeva Systems during the 2nd quarter worth about $169,000. Finally, Cerebellum GP LLC boosted its stake in shares of Veeva Systems by 1,645.0% during the 2nd quarter. Cerebellum GP LLC now owns 2,251 shares of the technology company’s stock worth $173,000 after acquiring an additional 2,122 shares in the last quarter. Hedge funds and other institutional investors own 76.02% of the company’s stock.
About Veeva Systems
Veeva Systems Inc provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, and internationally. The company offers Veeva Commercial Cloud, a suite of multichannel customer relationship management applications, data solutions, and master data management solutions; and Veeva Vault, a cloud-based enterprise content management applications for managing commercial functions, including medical, sales, and marketing, as well as research and development functions, such as clinical, regulatory, quality, and safety.
Further Reading: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.